News

DURHAM, NC, June 26, 2024 — Vogenx, a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced positive results from study VGX 001-012 evaluating Mizagliflozin in patients diagnosed with post-bariatric hypoglycemia (PBH).  Mizagliflozin is an investigational first-in-class, oral, small molecule drug candidate that reduces postprandial glucose absorption and secretion […]

Durham, N.C., April 2, 2024 – Vogenx, Inc., a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced that it has completed dosing of the last patient in its Phase 2 clinical study VGX-001-012 evaluating Mizagliflozin in patients diagnosed with post-bariatric hypoglycemia (PBH). Mizagliflozin is an investigational first-in-class,

DURHAM, N.C., February 15, 2024 – Vogenx, Inc., a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced completion of patient enrollment of a mid-Phase 2 clinical dose ranging study (VGX-001-012) evaluating Mizagliflozin in patients diagnosed with post-bariatric hypoglycemia (PBH). “Completing enrollment of this study is a significant

DURHAM, N.C., August 1, 2023 – Vogenx, a clinical-stage developer of novel therapeutics for the treatment of rare and metabolic disease, announced today the initiation of a Phase 2 clinical study of mizagliflozin for the treatment of post-bariatric hypoglycemia (PBH). PBH is a debilitating complication of bariatric surgery leading to recurrent postprandial hypoglycemia with neuroglycopenia.

DURHAM, NC / June 30, 2023 / Vogenx, a clinical-stage developer of novel therapeutics for the treatment of metabolic disease, today announced positive results from study VGX 001-011 (NCT05541939). This phase 2 study was a multi-center, randomized, sequential crossover, single ascending dose study evaluating mizagliflozin in patients who suffer from post-bariatric hypoglycemia (PBH), a debilitating complication

Vogenx to Present New Phase 2 Clinical Data on Mizagliflozin at the Endocrine Society (ENDO) 2023 Annual Conference May 30, 2023 DURHAM, NC. — Vogenx, Inc., an emerging, clinical-stage biopharmaceutical company developing novel, therapeutics to address unmet needs in metabolic disease, today announced that it will present new phase 2 clinical data (NCT05541939) at the Endocrine

Vogenx Announces Completion of Phase 2 Clinical Study of Mizagliflozin for Post Bariatric Hypoglycemia DURHAM, N.C., March 24, 2023, Vogenx, Inc. – Vogenx, a clinical-stage developer of novel therapeutics for the treatment of metabolic disease, today announced the successful completion of a Phase 2 clinical study of mizagliflozin for the treatment of post bariatric hypoglycemia

Vogenx Announces Initiation of Phase 2 Clinical Study of Mizagliflozin for Post Bariatric Hypoglycemia DURHAM, N.C., September 13, 2022, Vogenx Inc. – Vogenx, a clinical-stage developer of novel therapeutics for the treatment of metabolic disease, announced the screening of the first patient in a Phase 2 clinical study of mizagliflozin for the treatment of post

DURHAM, N.C., February 1, 2022: Vogenx, Inc., a clinical-stage developer of novel therapeutics for the treatment of metabolic disease, announced the closing of its Series A financing. Proceeds from the Series A preferred stock issuance will be used to advance the Company’s therapeutic product candidate, mizagliflozin, into phase 2 clinical trials. Concurrent with the financing,